Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
HRMY 
Harmony Biosciences Holdings (HRMY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: HRMY (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $43.91
1 Year Target Price $43.91
| 5 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -37.8% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.49B USD | Price to earnings Ratio 8.37 | 1Y Target Price 43.91 |
Price to earnings Ratio 8.37 | 1Y Target Price 43.91 | ||
Volume (30-day avg) 9 | Beta 0.79 | 52 Weeks Range 25.57 - 41.61 | Updated Date 10/17/2025 |
52 Weeks Range 25.57 - 41.61 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 3.1 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 23.42% | Operating Margin (TTM) 24.03% |
Management Effectiveness
Return on Assets (TTM) 14.1% | Return on Equity (TTM) 27.58% |
Valuation
Trailing PE 8.37 | Forward PE 6.13 | Enterprise Value 1146393402 | Price to Sales(TTM) 1.93 |
Enterprise Value 1146393402 | Price to Sales(TTM) 1.93 | ||
Enterprise Value to Revenue 1.48 | Enterprise Value to EBITDA 4.33 | Shares Outstanding 57532601 | Shares Floating 50606826 |
Shares Outstanding 57532601 | Shares Floating 50606826 | ||
Percent Insiders 11.07 | Percent Institutions 95.28 |
Upturn AI SWOT
Harmony Biosciences Holdings
Company Overview
History and Background
Harmony Biosciences Holdings, Inc. was founded in 2017. It focuses on developing and commercializing therapies for rare neurological diseases. Its key milestone is the approval and launch of WAKIX. The company has expanded through organic growth and strategic acquisitions.
Core Business Areas
- Narcolepsy: Focuses on the development and commercialization of treatments for narcolepsy, particularly excessive daytime sleepiness (EDS) and cataplexy.
Leadership and Structure
Harmony Biosciences is led by a management team with experience in the pharmaceutical industry. The organizational structure is built around core functions such as R&D, commercial operations, and corporate strategy.
Top Products and Market Share
Key Offerings
- WAKIX (pitolisant): WAKIX is a histamine-3 (H3) receptor antagonist/inverse agonist indicated to treat excessive daytime sleepiness (EDS) in adult patients with narcolepsy, with or without cataplexy. WAKIX has a significant market share in the narcolepsy treatment space. Competitors include Xyrem/Xywav (Jazz Pharmaceuticals), Sunosi (Axsome Therapeutics), and stimulants like Adderall.
Market Dynamics
Industry Overview
The market for narcolepsy treatments is growing, driven by increased awareness and diagnosis rates, as well as the introduction of novel therapies.
Positioning
Harmony Biosciences is positioned as an innovator in the narcolepsy treatment market with WAKIX. Its competitive advantage lies in its unique mechanism of action and convenient once-daily dosing.
Total Addressable Market (TAM)
The total addressable market for narcolepsy treatments is estimated to be in the billions of dollars. Harmony Biosciences aims to capture a significant portion of this market through continued growth of WAKIX and potential expansion into new indications.
Upturn SWOT Analysis
Strengths
- Novel mechanism of action of WAKIX
- Strong commercial execution
- Focus on rare neurological diseases
- Experienced management team
Weaknesses
- Reliance on a single product (WAKIX)
- Competition from established players
- Regulatory risks associated with drug development
- Relatively small company size compared to competitors
Opportunities
- Expansion into new indications (e.g., idiopathic hypersomnia)
- Geographic expansion to international markets
- Acquisition of complementary assets
- Development of next-generation therapies
Threats
- Patent expiration of WAKIX
- Increased competition from new entrants
- Pricing pressures from payers
- Unfavorable regulatory changes
Competitors and Market Share
Key Competitors
- JAZZ
- AXSM
Competitive Landscape
Harmony Biosciences faces competition from established pharmaceutical companies with larger resources. However, its focus on narcolepsy and unique product profile give it a competitive edge.
Growth Trajectory and Initiatives
Historical Growth: Harmony Biosciences has experienced significant growth since the launch of WAKIX.
Future Projections: Future growth is projected to be driven by continued sales growth of WAKIX and potential expansion into new indications.
Recent Initiatives: Recent initiatives include ongoing clinical trials for new indications and strategic partnerships.
Summary
Harmony Biosciences is a growing pharmaceutical company focused on rare neurological diseases, particularly narcolepsy. Its key asset, WAKIX, drives revenue growth, but the company's reliance on a single product poses a risk. Successful expansion into new indications and geographies, along with prudent financial management, are critical for continued success. Competition from larger pharmaceutical companies and potential patent expirations are key threats to watch out for.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website, SEC filings, Analyst reports, Market research reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market data can change rapidly and is subject to inherent uncertainties. Investment decisions should be made with the help of a qualified financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Harmony Biosciences Holdings
Exchange NASDAQ | Headquaters Plymouth Meeting, PA, United States | ||
IPO Launch date 2020-08-19 | President, CEO & Director Dr. Jeffrey M. Dayno M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 268 | |
Full time employees 268 | |||
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 1 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome (FXS), rare genetic disorder that causes inherited intellectual disability and autism spectrum disorder; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; and EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies (DEE). The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.